Track records, product handling limitations, and cost are all factors to consider when outsourcing parenteral manufacturing. Choosing the right CDMO partner is not an easy task, but Curia has resources to make the decision easier. To learn more, Pharmaceutical Technology sat down with Dr. Ronald Aungst [Vice President, Portfolio and Sourcing for Drug Product, Curia] to discuss what CDMOs have to offer and how these partnerships can improve tech transfers and drug product development.
More from Curia
While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lin...